



Published in final edited form as:

Cancer Discov. 2019 December ; 9(12): 1673–1685. doi:10.1158/2159-8290.CD-19-0338.

Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11

Xueting Lang^{1,2,3,†}, Michael D. Green^{2,3,†}, Weimin Wang^{1,2}, Jiali Yu^{1,2}, Jae Eun Choi^{2,4,5}, Long Jiang^{2,3}, Peng Liao^{1,2}, Jiajia Zhou^{1,2}, Qiang Zhang^{2,3}, Ania Dow¹, Anjali L. Saripalli⁶, Ilona Kryczek^{1,2}, Shuang Wei^{1,2}, Wojciech Szeliga^{1,2}, Linda Vatan^{1,2}, Everett M. Stone^{7,8}, George Georgiou^{7,8}, Marcin Cieslik^{4,9,10}, Daniel R. Wahl³, Meredith A. Morgan³, Arul M. Chinnaiyan^{4,5,9,10}, Theodore S. Lawrence³, Weiping Zou^{1,2,4,11,12,*}

¹Department of Surgery, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

²Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

³Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

⁴Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

⁵Michigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

⁶Department of Medical Education, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

⁷Department of Chemical Engineering, University of Texas at Austin, TX, USA.

⁸Department of Molecular Biosciences, University of Texas at Austin, TX, USA.

⁹Department of Computational Medicine & Bioinformatics, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

¹⁰Howard Hughes Medical Institute, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

¹¹Graduate Program in Immunology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

¹²Graduate Program in Cancer Biology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

Abstract

A challenge in oncology is to rationally and effectively integrate immunotherapy with traditional modalities including radiotherapy. Here, we demonstrate that radiotherapy induces tumor cell

*Correspondence to: Weiping Zou, MD, PhD, University of Michigan School of Medicine, BSRB 5071, 109 Zina Pitcher Place, Ann Arbor MI 48109-0669, wzou@med.umich.edu, phone: (734)763-6402.

†Xueting Lang and Michael D. Green contributed equally to this work

Conflict of Interest: The authors declare no competing financial interests.

ferroptosis. Ferroptosis agonists augment and ferroptosis antagonists limit radiotherapy efficacy in tumor models. Immunotherapy sensitizes tumors to radiotherapy by promoting tumor cell ferroptosis. Mechanistically, IFN γ derived from immunotherapy-activated CD8⁺ T cells and radiotherapy-activated ATM independently, yet synergistically repress SLC7A11, a unit of the glutamate-cystine antiporter xc⁻, resulting in reduced cystine uptake, enhanced tumor lipid oxidation and ferroptosis, and improved tumor control. Thus, ferroptosis is an unappreciated mechanism and focus for the development of effective combinatorial cancer therapy.

Keywords

Radiotherapy; ferroptosis; tumor immunology; interferon signaling; cancer metabolism

Introduction

Immune checkpoint blockade is a powerful oncologic treatment modality for a wide variety of human malignancies (1). Randomized clinical trials are assessing how best to interdigitate this treatment modality with traditional therapies including radiotherapy (2). Thus far, preclinical data has suggested that immune checkpoint blockade can synergize with radiotherapy through agonism of innate immune sensing pathways activated as a consequence of DNA damage (3-5).

It is well established that unrepaired DNA double strand breaks dictate cellular survival following radiotherapy (6). These lesions promote mitotic catastrophe, an unregulated form of cell death (7). More recent examinations have implicated a number of other forms of regulated cell death, including apoptosis, necroptosis, and autophagy in the response to radiotherapy (8,9). Radiotherapy stochastically induces oxidative damage in all cellular compartments, including the lipid membrane (10,11). Toxic lipid peroxidation accumulation only recently been implicated in directly causing a regulated form of cell death, termed ferroptosis (12). The sources of cell death inducing reactive oxygen species (ROS) that predispose cells to undergo ferroptosis have not been defined. It has been suggested that radiation induced lipid oxidation results in apoptosis (13), but the relationship between radiotherapy and ferroptosis remains undefined. Further, radiotherapy efficacy *in vivo* is dependent on the presence of CD8⁺ T cells (14,15). We have recently discovered that CD8⁺ T cells modulate tumoral ferroptosis through IFN γ (16). It is unknown if ferroptosis underlies the interplay between the adaptive immune system and radiotherapy.

To address these questions, we explored the involvement of lipid peroxidation and ferroptosis in response to radiotherapy. We implicate ferroptosis as a previously unknown mechanism of tumor cell death following radiotherapy *in vitro* and *in vivo*. In addition, we have found that radiotherapy can sensitize tumor cells to ferroptosis agonists *in vitro* and *in vivo*, highlighting a novel strategy to radiosensitize tumors. Moreover, we have implicated ferroptosis as a direct link through which CD8⁺ T cells and radiotherapy cooperate to improve tumor control. Mechanistically, IFN γ derived from immunotherapy-activated CD8⁺ T cells and Ataxia- Telangiectasia mutated gene (ATM) activated following radiotherapy synergistically suppress solute carrier family 7 member 11 (SLC7A11), a unit of the

glutamate-cystine antiporter x_c^- , resulting in enhanced tumor lipid oxidation and ferroptosis. This work is the first to nominate radiotherapy as a therapeutic ferroptosis inducer and suggest ferroptosis agonists as a novel class of sensitizers for radiotherapy and immunotherapy. Finally, our studies highlight lipid peroxidation as a previously unappreciated point of mechanistic interplay between radiotherapy and immunotherapy in cancer.

Results

Radiotherapy induces tumor cell ferroptosis

Ferroptosis is a recently discovered form of cell death that differs from apoptosis and results from iron-dependent lipid peroxide accumulation (12,17). It is unknown whether lipid oxidation and ferroptosis are induced by radiotherapy. To test this *in vivo*, we inoculated ID8 ovarian cancer cells into the peritoneal cavity of C57BL/6 mice and treated the mice with a single dose of 8 Gray (Gy) of ionizing radiation, liproxstatin-1, a ferroptosis antagonist, or both agents concurrently. ID8 tumor bearing mice tolerated radiotherapy without changes in mouse weight (Supplementary Fig. S1A). Radiotherapy, but not liproxstatin-1, reduced tumor growth (Fig. 1A). Unexpectedly, liproxstatin-1 administration concurrent and adjuvant to radiotherapy diminished radiotherapy efficacy (Fig. 1A).

To extend this finding, we inoculated B16F10 melanoma cells into C57BL/6 mice and allowed the tumors to establish. Subsequently, B16F10 bearing mice were treated with a single fraction of 8 Gy. Again, radiotherapy reduced tumor growth (Supplementary Fig. S1B). Dual treatment with liproxstatin-1 and radiotherapy partially and significantly abrogated radiotherapy efficacy. Ferroptosis is accompanied by increased lipid peroxidation, which can be examined using the lipophilic redox sensitive dye C11BODIPY (12). C11BODIPY quantification showed that radiotherapy increased lipid peroxidation *in vivo*, and concurrent liproxstatin-1 treatment abrogated radiotherapy induced lipid peroxidation in B16F10 tumors (Fig. 1B and Supplementary Fig. S1C).

To orthogonally confirm tumoral ferroptosis occurs following radiotherapy, we generated ferroptosis resistant subclones of B16F10 through serial exposure to RSL-3, a ferroptosis agonist. We showed that RSL-3 resistant B16F10 cells were indeed resistant to RSL-3 and erastin, two ferroptosis agonists (Supplementary Fig. S1D). We then inoculated parental or RSL-3 resistant B16F10 cells into C57BL/6 mice and treated established tumors with radiotherapy. We observed that resistance to ferroptosis significantly reduced the efficiency of radiotherapy (Fig. 1C). Further, RSL-3 resistant tumors failed to manifest a robust increase in lipid peroxidation following radiotherapy as compared to parental tumors (Fig. 1D). We additionally generated ferroptosis resistant ID8 subclones through serial exposure to erastin. We also showed that erastin resistant ID8 cells were resistant to RSL-3 and erastin (Supplementary Fig. S1E). We inoculated parental and erastin resistant ID8 cells into C57BL/6 mice and treated established ID8 tumors with radiotherapy. Again, we observed reduced radiotherapy efficacy in erastin resistant tumors (Fig. 1E). Together, these data suggest that radiotherapy induces tumor ferroptosis and also that ferroptosis is critical for radiotherapy efficacy.

To understand whether radiotherapy directly induces tumor ferroptosis, we performed clonogenic survival assay following radiotherapy in HT1080 human fibrosarcoma cells *in vitro*. We observed that ferroptosis inhibitors, liproxstatin-1 and ferrostatin-1, the lipophilic antioxidant trolox, and the iron chelator deferoxamine (DFO) increased clonogenic cell survival following radiotherapy (Fig. 1F). To determine whether radiotherapy directly affected lipid peroxidation, we conducted C11BODIPY staining in HT1080 cells *in vitro*. We observed that radiotherapy resulted in an increase in lipid ROS in HT1080 cells (Fig. 1G). We next examined clonogenic cell survival and lipid peroxidation in B16F10 and ID8 cells. Again, liproxstatin-1, as well as trolox and DFO, enhanced clonogenic survival in B16F10 (Supplementary Fig. S1F) and ID8 (Supplementary Fig. S1G) cells following radiotherapy. Radiotherapy induced an increased lipid peroxidation in B16F10 cells (Supplementary Fig. S1H) and ID8 cells (Supplementary Fig. S1I) in dose dependent manner. These results suggest that radiotherapy directly induces tumor ferroptosis.

Given that radiotherapy can induce tumor ferroptosis (Fig. 1A-1G and Supplementary Fig. S1A-S1I), we wondered whether ferroptosis agonists could enhance radiotherapy efficacy and be exploited as novel radiosensitizers. To explore this possibility, we pretreated HT1080, B16F10, and ID8 cells with low doses of ferroptosis inducers (FINs) including sulfasalazine, RSL-3, erastin, and atorvastatin, and then irradiated these cells. We found that ferroptosis inducers reduced clonogenic cell survival as compared to radiotherapy alone in HT1080 cells *in vitro* (Fig. 1H). GPX4 utilizes glutathione to reduce oxidized lipid species and to limit ferroptosis. Glutathione levels are regulated by intracellular cystine concentrations. We depleted cystine and cysteine using cyst(e)inase, a recombinant human enzyme (18). Interestingly, cyst(e)inase strongly sensitized HT1080 cells to radiotherapy *in vitro* (Fig. 1I).

To support our finding in HT1080, we treated B16F10 cells with sulfasalazine, RSL-3, and cyst(e)inase and observed decreased cell survival following radiotherapy as compared to radiotherapy alone (Supplementary Fig. S1J, S1K). Cell death quantification using propidium iodide staining confirmed that sulfasalazine and cyst(e)inase augmented radiation induced cell death (Fig. 1J). Pretreatment with RSL-3, sulfasalazine, cyst(e)inase also increased ID8 cell sensitivity to radiotherapy *in vitro* (Supplementary Fig. S1L, S1M). To examine the relevance of this finding *in vivo*, we established B16F10 tumors in C57BL/6 mice and treated mice with cyst(e)inase, radiotherapy, or the combination. While cyst(e)inase had minimal efficacy as monotherapy, it enhanced radiotherapy efficiency (Fig. 1K). Moreover, increased tumor control was accompanied with enhanced lipid oxidation in the combination therapy group (Fig. 1L). Neither single treatment nor the combination treatment caused significant murine weight loss (Supplementary Fig. S1N).

To assess whether FINs can improve radiotherapy efficacy *in vivo*, we established B16F10 tumors in mice, and treated tumors with radiotherapy, sulfasalazine, or both (dual treatment). We found that dual treatment enhanced tumor control (Supplementary Fig. S1O). Again, this improved tumoral control was accompanied with increased lipid oxidation in tumors treated with both agents (Supplementary Fig. S1P). These data suggest that ferroptosis can be targeted *in vivo* to enhance radiotherapy efficacy.

It has recently been shown that fatty acid saturation modulates ferroptosis sensitivity. Specifically, long-chain-fatty-acid-CoA ligase 4 (ACSL4) promotes ferroptosis, while ACSL3 limits ferroptosis (19,20). We generated ACSL4 knockout and ACSL3 knockout B16F10 cells (Supplementary Fig. S1Q, S1R). We observed that loss of the ferroptosis effector gene ACSL4 diminished radiotherapy efficacy *in vivo* (Fig. 1M). In contrast, deletion of the ferroptosis suppressor ACSL3 augmented radiotherapy efficacy *in vivo* (Fig. 1N).

To demonstrate that diminished cell survival following radiation was due to increased lipid peroxidation and ferroptosis, we quantified lipid peroxidation changes with C11BODIPY following FIN addition. We observed that in B16F10 cells, short exposures to low doses of sulfasalazine, RSL-3, and cyst(e)inase minimally altered lipid ROS. Combinations of FINs with radiation synergistically increased lipid ROS (Fig. 1O). FINs similarly augmented lipid ROS levels in concert with radiation in HT1080 cells (Supplementary Fig. S1S).

To generalize these findings to different radiation doses and fractionation schedules, we treated B16F10 tumors with 5 fractions of 3 Gy as well as a single fraction of 10 Gy or 20 Gy. Quantification of lipid peroxidation changes with C11BODIPY showed that all radiotherapy doses induced increases in C11BODIPY, while higher single fractions of radiotherapy induced more lipid peroxidation (Fig. 1P). To confirm that ferroptosis resistance conferred radiotherapy resistance at ablative doses of radiotherapy, we treated WT and RSL3 resistant B16F10 tumors with a single fraction of 20 Gy (21). We observed that even at higher doses of radiotherapy, ferroptosis resistant tumors remained resistant to radiotherapy *in vivo* (Supplementary Fig. S1T).

Collectively, these data suggest that radiation induces tumor ferroptosis and this ferroptosis can be pharmacologically augmented by ferroptosis agonists. Thus, targeting ferroptosis may be a novel therapeutic approach for radiation sensitization.

CD8⁺ T cells promote radiotherapy induced ferroptosis via IFN γ

CD8⁺ T cells are required for efficacy of ablative doses of radiotherapy *in vivo* (21,22). The cellular and molecular bases for the interaction between T cells and radiotherapy are not fully defined. We first examined the involvement of CD8⁺ T cells in radiation therapy efficacy in B16F10 tumor bearing mouse model at moderate clinically utilized radiation doses. We subcutaneously inoculated B16F10 cells into C57BL/6 and established tumors. Then, mice received a moderate dose of radiation (8 Gy) alone or with anti-CD8 monoclonal antibody (mAb) administration prior to radiotherapy. As expected, radiotherapy reduced tumor volume (Fig. 2A). However, CD8⁺ T cell depletion with anti-CD8 mAb treatment largely abolished radiotherapy-induced tumor reduction (Fig. 2A). This radiation dose induced tumor cell ferroptosis (Supplementary Fig. S1B, S1H). To understand if CD8⁺ T cells promoted ferroptosis in concert with radiotherapy, we treated B16F10 cells with naïve or activated T cell supernatant. We found that exposure to a low dose of T-cell supernatant had minimal effect on B16F10 cell survival. Interestingly, T-cell supernatant synergized with radiotherapy to limit B16F10 clonogenic cell survival (Fig. 2B). Furthermore, T-cell supernatant and radiotherapy each independently enhanced lipid peroxidation in B16F10 cells, their combination further augmented lipid peroxidation (Fig. 2C). Blockade of IFN γ

signaling decreased T-cell supernatant-induced tumor STAT1 phosphorylation (Supplementary Fig. S2A) and diminished tumor lipid ROS production following combination treatment with T-cell supernatant and radiotherapy (Fig. 2C). These results suggest that CD8⁺ T cells may promote tumor ferroptosis and induce radiosensitization via IFN γ .

To assess a direct link between IFN γ signaling and radiotherapy efficacy, we treated ID8 cells with IFN γ and radiotherapy and examined clonogenic cell survival. We observed that IFN γ and radiotherapy synergistically reduced clonogenic survival (Fig. 2D). We also observed diminished clonogenic cell survival following IFN γ and radiation treatment in B16F10 cells (Supplementary Fig. S2B). IFN γ and radiotherapy synergistically increased lipid ROS levels in ID8 cells (Fig. 2E), B16F10 cells (Supplementary Fig. S2C), and HT1080 cells (Supplementary Fig. S2D). To confirm that IFN γ increased radiation induced cell death, we quantified PI⁺ dying B16F10 cells following treatment with IFN γ , radiotherapy treatment or the combination. We observed a synergistic increase in cell death following combination treatment of radiotherapy and IFN γ (Fig. 2F). To implicate ferroptosis in cell death induced by the combination treatment of radiotherapy and IFN γ , we conducted clonogenic survival in HT1080 cells with IFN γ , radiotherapy, and liproxstatin-1. We observed that liproxstatin-1 administration blocked the synergistic reduction of cell survival observed upon treatment with IFN γ and radiotherapy (Fig. 2G and Supplementary Fig. S2E). The data indicates that the combination of IFN γ and radiotherapy regulates tumor cell ferroptosis *in vitro*. To examine that IFN γ alters radiotherapy efficacy *in vivo*, we inoculated HT1080 cells into NOD-scid IL2 γ c-deficient (NSG) mice, and treated mice with recombinant human IFN γ , radiotherapy, or the combination. While low doses of IFN γ and radiotherapy slightly diminished tumor growth, the combination potentially promoted tumor regression (Fig. 2H). To assess whether this is associated with tumor ferroptosis, we performed immunohistochemistry staining in tumor tissues and quantified 4-hydroxynoneal (4-HNE), a lipid peroxidation byproduct (23). Indeed, combination treatment with IFN γ and radiotherapy significantly increased the tumoral 4-HNE levels (Fig. 2I and Supplementary Fig. S2F). To functionally demonstrate ferroptosis contributed to synergistic tumor regression *in vivo*, we inoculated HT1080 cells into NSG mice and treated mice with IFN γ plus radiotherapy, liproxstatin-1, or all three agents. As expected, IFN γ plus radiotherapy induced tumor regression. Importantly, this effect was abrogated by simultaneous treatment with liproxstatin-1 (Fig. 2J). Together, these data demonstrate that CD8⁺ T cells directly sensitize tumor cells to radiotherapy through IFN γ by increasing lipid peroxidation and ferroptosis.

Radiotherapy and IFN γ synergistically suppress system SLC7A11

We next sought to define the molecular mechanism by which IFN γ sensitizes radiotherapy and promotes tumor ferroptosis. We first performed unbiased RNA sequencing in HT1080 cells following treatment with IFN γ , radiotherapy, or the combination. Consistent with published results, interferon response genes, including CXCL9 and IRF1, were upregulated strongly by IFN γ treatment (Fig. 3A) (24). As expected, radiotherapy induced an ATM dependent transcriptional program (25). Dual treatment with radiotherapy and IFN γ surprisingly downregulated multiple cystine and cysteine transport channels, including a

component of the cystine-glutamate transporter system x_c^- , SLC7A11 (Fig. 3A), which is a critical regulator of ferroptosis (26). Other ferroptosis regulators including GPX4, ACSL4, LPCAT3, and lipoxygenases (Supplementary Fig. S3A, S3B) were not altered in the same manner by dual treatment with radiotherapy plus IFN_γ treatment. We next validated this finding. Treatment with IFN_γ and radiotherapy individually reduced SLC7A11 transcripts (Fig. 3B) and protein levels (Fig. 3C) in HT1080 cells. Dual treatment resulted in a dramatic reduction of SLC7A11 in HT1080 cells (Fig. 3B, 3C). We also performed immunohistochemistry staining for SLC7A11 in HT1080 tumor tissues (Fig. 2H) and found IFN_γ and radiotherapy reduced SLC7A11 expression *in vivo* (Fig. 3D). To determine the functional relevance of SLC7A11 reduction, we examined radiolabeled cystine uptake in HT1080 cells. While both radiation and IFN_γ each reduced cystine uptake, dual treatments resulted in a maximal decrease in cystine uptake in HT1080 cells (Fig. 3E). Cystine is a precursor for glutathione production, which is a required cofactor for GPX4 activity (27). To confirm that diminished cystine import altered cellular antioxidant stores, we quantified glutathione level in HT1080 cells following treatment with radiation, IFN_γ , and the combination. We observed that the combination treatment significantly decreased glutathione level (Fig. 3F). Thus, radiotherapy and IFN_γ synergistically downregulate SLC7A11 expression in tumor cells resulting in diminished cystine transport and depletion of antioxidant stores in tumor cells to induce ferroptosis.

Next, we explored how radiotherapy downregulates SLC7A11 in tumor cells. Cells respond to radiotherapy through defined signaling cascades, including ATM activation (6,25,28). ATM has recently been shown to promote ferroptosis (29). We wondered whether ATM activation is involved in radiation induced ferroptosis by regulating SLC7A11. To test this possibility, we treated HT1080 cells with KU60019 (30), an ATM inhibitor. ATM inhibition abrogated radiotherapy-mediated downregulation of SLC7A11 transcription (Supplementary Fig. S3C) and protein levels (Fig. 3G). Indeed, treatment with KU60019 diminished radiotherapy-induced lipid peroxidation in HT1080 cells (Fig. 3H). Further, siRNA targeting ATM prevented downregulation of SLC7A11 transcription (Supplementary Fig. S3D) and protein (Fig. 3I) following radiotherapy. To confirm this mechanism *in vivo*, we treated wild type and shATM HT1080 tumors with radiotherapy (Supplementary Fig. S3E). We observed that wild type, but not ATM silenced tumors showed downregulation of SLC7A11 expression (Fig. 3J, Supplementary Fig. S3F). Further, wild type tumors showed increased 4-HNE lipid peroxidation *in vivo* following radiotherapy as compared to ATM silenced tumors (Supplementary Fig. S3G, S3H). Therefore, radiotherapy transcriptionally represses SLC7A11 expression via ATM to promote tumoral ferroptosis.

We have previously reported that IFN_γ negatively regulates SLC7A11 expression in a JAK-STAT1 dependent manner (16,31). To validate this finding, we silenced STAT1 with siRNAs (si-STAT1) in HT1080 cells and found that IFN_γ downregulated SLC7A11 in STAT1 dependent manner (Supplementary Fig. S3I and Fig. 3K). Interestingly, IFN_γ efficiently and comparably reduced SLC7A11 expression in both ATM-proficient and ATM-deficient HT1080 cells (Supplementary Fig. S3J). Conversely, regardless of STAT1 expression, radiotherapy efficiently reduced SLC7A11 expression in HT1080 cells (Supplementary Fig. S3K). Thus, radiotherapy and IFN_γ synergistically repress tumor SLC7A11 through ATM and STAT1 signaling, respectively. To confirm this mechanism *in vivo*, we treated wild type

and STAT1 knockout HT1080 tumors with IFN γ (Supplementary Fig. S3L). We observed that wild type but not STAT1 deficient tumors showed SLC7A11 downregulation following IFN γ treatment (Fig. 3L and Supplementary Fig. S3M). We also observed that wild type tumors showed increased 4-HNE lipid oxidation following IFN γ treatment as compared to STAT1 knockout tumors (Supplementary Fig. S3N, S3O).

To functionally connect SLC7A11 to tumor ferroptosis induced by radiotherapy, we used small hairpin RNAs against SLC7A11 (shSLC7A11) to knock down SLC7A11 in HT1080 cells (Supplementary Fig. S3P). We found that knockdown of SLC7A11 promoted radiotherapy-induced cell death in HT1080 cells (Fig. 3M) and B16F10 cells (Supplementary Fig. S3Q). This effect was rescued by liproxstatin-1 in HT1080 cells (Fig. 3M) and B16F10 cells (Supplementary Fig. S3Q). To determine the importance of SLC7A11 in radiotherapy *in vivo*, we used CRISPR-Cas9 to delete SLC7A11 in B16F10 cells. We confirmed deletion by quantifying SLC7A11 mRNA levels, and consistent with loss of system xc⁻ function, knockout cells were unable to export glutamate (Supplementary Fig. S3R, S3S). In line with previous reports (12,26), we found SLC7A11 deficient cells underwent spontaneous cell death, which can be rescued by liproxstatin-1 or 2-mercaptoethanol (BME) (Supplementary Fig. S3T). We inoculated SLC7A11 proficient and deficient B16F10 tumors into C57BL/6 mice, and treated mice with radiotherapy. Radiotherapy efficacy was enhanced in SLC7A11 deficient cells *in vivo* (Fig. 3N). Examination of lipid peroxidation showed that SLC7A11 deficient tumors had increased baseline levels of lipid ROS (Fig. 3O). Moreover, radiotherapy induced alterations in lipid peroxidation was further increased by loss of SLC7A11 (Fig. 3O). To confirm the importance of SLC7A11 to survival following combination IFN γ and radiotherapy, we overexpressed SLC7A11 in HT1080 cells (Supplementary Fig. S3U). We observed that overexpression significantly increased clonogenic survival following treatment with radiotherapy and IFN γ (Fig. 3P). To further confirm the importance of SLC7A11 expression, we performed rescue experiments in which SLC7A11 was expressed in SLC7A11 deficient cells (Supplementary Fig. S3V). Additionally, we observed that overexpression of SLC7A11 reversed the sensitivity of SLC7A11 deficient tumors to radiotherapy *in vivo* (Fig. 3Q). Collectively, these results suggest that radiotherapy activated ATM and IFN γ induced STAT1 signaling jointly target SLC7A11 to modulate cystine uptake and promote tumor lipid peroxidation and ferroptosis.

Radiotherapy and immunotherapy synergistically induce tumoral ferroptosis

Immunotherapy augments radiotherapy efficacy *in vivo*, but the mechanisms through which immune checkpoint blockade enhances tumor cell death in irradiated lesions are not well defined (4,32,33). Checkpoint therapy including anti-PD-L1 and anti-CTLA4 activates CD8⁺ T cells and potentiates IFN γ signaling pathway to control tumor progression (1). We hypothesized that radiotherapy and immunotherapy would synergize via ferroptosis *in vivo* to improve the efficacy of both therapies. To test this hypothesis, we established B16F10 tumors in C57BL/6 mice and treated mice with anti-CTLA4 mAb, radiotherapy, or the combination. As previously reported, anti-CTLA4 monotherapy was minimally efficacious in B16F10 tumors (32). However, we found that it potentiated radiotherapy efficacy in irradiated tumors (Fig. 4A). Consistent with our observation (Fig. 1), radiotherapy increased

lipid peroxidation. Interestingly, the combination treatment with anti-CTLA4 and radiotherapy further enhanced tumoral lipid peroxidation (Fig. 4B). The combination of anti-CTLA4 and radiotherapy enhanced CD8⁺ T trafficking into tumors (Supplementary Fig. S4A, S4B). Radiotherapy increased tumor infiltrating Ki67⁺CD8⁺ T cells and this was augmented by anti-CTLA-4 (Fig. 4C and Supplementary Fig. S4C). Furthermore, we detected enhanced CD8⁺ T cell function following combined anti-CTLA4 and radiotherapy as marked by increased IFN_γ and granzyme B production (Fig. 4D, 4E and Supplementary Fig. S4D, S4E). Similarly, we observed that combination therapy increased CD4⁺ T cell number and IFN_γ expression (Supplementary Fig. S4F, S4G). To determine whether tumor ferroptosis contributed to the synergy between anti-CTLA4 and radiotherapy *in vivo*, we inoculated B16F10 tumors in C57BL/6 mice and treated them with the combination of anti-CTLA4 plus radiotherapy, liproxstatin-1, or all three treatments. Interestingly, liproxstatin-1 diminished the combined therapeutic efficacy of anti-CTLA4 and radiotherapy as shown by tumor volume (Fig. 4F), as well as tumor lipid peroxidation (Supplementary Fig. S4H). To extend our findings to an additional model, we inoculated ID8 tumors into the peritoneal cavities of C57BL/6 mice, and treated mice with anti-CTLA4, radiotherapy, or the combination. Anti-CTLA-4 and radiotherapy synergistically enhanced tumor control *in vivo* (Fig. 4G). Again, we observed increased lipid peroxidation following radiotherapy, and anti-CTLA4 mediated enhancement of lipid peroxidation following dual treatment with radiotherapy and anti-CTLA4 (Fig. 4H). To explore if other forms of immune checkpoint blockade also induced lipid peroxidation, we established B16F10 tumors in mice and treated the tumors with radiotherapy, anti-PD-L1, or both. While anti-PD-L1 or radiotherapy alone controlled tumor growth, the dual treatment was more effective in reducing tumor growth than any single therapy (Fig. 4I). We also detected the highest levels of tumor lipid peroxidation following combination therapy (Fig. 4J).

SLC7A11 deficient cells were more sensitive to radiotherapy *in vitro* and *in vivo* because of their increased ferroptosis susceptibility (Fig. 3). We hypothesized that ferroptosis sensitive tumors may benefit more from immune checkpoint blockade. To examine this, we established SLC7A11 proficient or deficient B16F10 tumors in C57BL/6 mice, and treated mice with anti-PD-L1. We detected higher tumoral lipid ROS in SLC7A11 deficient tumor cells than wild type tumor cells regardless of anti-PD-L1 therapy (Supplementary Fig. S4I). Furthermore, SLC7A11 deficient tumors were more sensitive to anti-PD-L1 therapy as shown by increased tumor C11BODIPY fluorescence and reduced tumor volume (Supplementary Fig. S4J) compared to wild type tumors.

To additionally support that ferroptosis is a mechanism of synergy between immunotherapy and radiotherapy, we inoculated parental or RSL-3 ferroptosis resistant cells into mice and treated mice with anti-PD-L1 and radiotherapy. We observed that in contrast to the parental cells, RSL-3 resistant B16F10 cells were largely insensitive to the combined treatment with anti-PD-L1 and radiotherapy (Fig. 4K). Moreover, this insensitivity was accompanied by diminished C11BODIPY in tumor cells (Fig. 4L). To define the mechanisms contributing to resistance of therapy, we established ovalbumin expressing parental or RSL-3 ferroptosis resistant B16F10 tumors and treated the mice with OT-1 transgenic T cells. We observed that OT-1 therapy controlled wild type but not RSL-3 resistant tumor. This suggests that ferroptosis resistant tumors are resistant to T cell effector function (Fig. 4M).

To examine that SLC7A11 modulated the induction of durable immune responses, we established parental or SLC7A11 deficient B16F10 tumors and treated them with radiotherapy and anti-PD-L1 therapy. We observed that SLC7A11 deficient tumors were more sensitive to combination therapy, with complete long-term responses in 56% (14/25) of SLC7A11 deficient tumor inoculated mice (Fig. 4N). To test whether these mice developed immunologic memory, wild type B16F10 tumors were re-inoculated in cured mice. We noted that tumors established in control but not previously cured mice, suggestive of the establishment of T cell memory (Fig 4O). Collectively, these data suggest that immunotherapy synergizes with radiotherapy to induce tumor ferroptosis and establish T-cell immunity.

Discussion

A major challenge in oncology is how to rationally and effectively integrate PD-1/PD-L1 and CTLA-4 immune checkpoint blockade with traditional oncologic treatment modalities including radiotherapy (1). CD8⁺ T cells are required for the efficacy of both immunotherapy and radiotherapy. We have now demonstrated that effector T cells and radiotherapy interact through ferroptosis to promote tumoral clearance. Radiotherapy classically promotes tumor cell death primarily through the induction of double stranded DNA breaks in tumor cells which, if unrepaired, lead to mitotic catastrophe and unregulated tumor cell death (7). We provide the first evidence that radiation also promotes lipid peroxidation, resulting in tumoral ferroptosis. Concurrent administration of genotoxic agents to augment DNA damage has been harnessed clinically to improve radiotherapy efficacy and improve the outcomes of cancer patients. We have found that ferroptosis agonists can sensitize tumors to radiation both *in vitro* and *in vivo*, uncovering new therapeutic strategies to improve radiotherapy efficacy.

Ferroptosis is regulated by lipid metabolism, iron metabolism, and cysteine metabolism (34). ATM regulates cell survival following radiotherapy (25) and has also been shown to regulate ferroptosis (29). We have shown that radiotherapy activates ATM to suppress SLC7A11 expression, limit tumor cystine uptake, diminish glutathione, and increases lipid oxidative damage to mediate tumor cell ferroptosis. We have demonstrated that biochemical and genetic inhibition of ATM can prevent loss of SLC7A11 expression, reduce lipid oxidation, and rescue tumor cell ferroptosis induced by radiotherapy. Similarly, ATM promotes DNA damage repair and cell survival following radiation but is also required for radiation induced ferroptosis. Along this line, p53 both contributes to tumor cell survival, but is also promotes tumor cell death (35). Several pharmacologic inhibitors are being studied as radiosensitizers (36). Given that ATM signaling may play an unexpected role in promoting tumor cell ferroptosis, additional study is required to understand the context dependent consequence of ATM inhibition. Notably, we have focused on a role of SLC7A11 and ATM in radiotherapy-associated ferroptosis. We do not rule out that radiation may affect other ferroptosis-associated genes, which may collectively contribute to radiotherapy-mediated ferroptosis in different contexts.

CD8⁺ T cell tumor infiltration and IFN γ signaling pathway activation are key features of effective immunotherapy in cancer patients (1,37,38). We have recently shown that CD8⁺ T

cells modulate tumoral ferroptosis (16). We now extend this work showing CD8⁺ T cells can alter the sensitivity of tumor cells to radiotherapy by promoting ferroptosis. CD8⁺ T cell derived IFN γ and radiation coordinately inhibit tumor SLC7A11 expression to induce tumor cell ferroptosis. This translates into potent tumor immunity, tumor ferroptosis, and tumor regression in several murine models treated with the combination of radiotherapy and PD-L1/PD-1 or CTLA-4 blockade. Moreover, ferroptosis inhibition or resistance diminishes the synergy between immunotherapy and radiotherapy *in vivo*. The major immunosuppressive mechanisms in the tumor microenvironment include high levels of PD-L1 expression (39,40) and regulatory T-cell infiltration (41). Radiation can target PD-L1 expressing cells and regulatory T cells (15). More recently, cGAS-STING sensing of cytoplasmic DNA and micronuclei following radiation has emerged as an important connection between innate immunity and radiotherapy (3,4,32). Our work suggests that tumor ferroptosis is a novel intersection between radiotherapy and adaptive immunity.

In conclusion, this work highlights that ferroptosis may be untapped therapeutic mechanism and focus for the development of effective pharmacologic and immunotherapeutic combinatorial approaches with radiotherapy for the treatment of cancer.

Methods

Reagents

Ferrostatin-1 (347174-05-4), liproxstatin-1 (950455-15-9), trolox (53188-07-1), deferoxamine (138-14-7), RSL-3 (1219810-16-8), erastin (571203-78-6), sulfasalazine (599-79-1), atorvastatin (599-79-1), KU60019 (925701-46-8) were purchased from Cayman. The concentration used is shown in Supplementary Table. S1. C11BODIPY (D3861) was purchased from Invitrogen. Mouse recombinant IFN γ (485-MI-100), anti-mouse IFN γ block antibody (MAB485), human recombinant IFN γ (285-IF-100) were purchased from R&D. Anti-mouse IFNGR1 antibody (16-1193-85) was purchased from Thermo Fisher. The following antibody were used for immunoblots: anti-human SLC7A11 antibody (12691), anti- β -actin (12262), anti-GAPDH (2118), anti-STAT1 (9172), anti-phospho-STAT1 (9167), anti-ATM (2873) and anti-ACSL4 (4047) were bought from Cell Signaling Technology. Anti-GPX4 (ab41787) was from Abcam. Additionally, IgG (BE0087, BE0090), anti-mouse CTLA4 (BE0131), anti-mouse PD-L1 (BE0101) and anti-mouse CD8 (BE0117) were purchased from BioXcell. 4-HNE antibody (ab46545) was purchased from Abcam. Cyst(e)inase was generated as previously described (18).

Cell lines

All the cell lines used here, including B16F10, ID8, HT1080 and HEK-293T cell lines, were bought from ATCC. Cells were regularly tested for Mycoplasma contamination using the Adenosine 5'-triphosphate (ATP) Bioluminescent Assay Kit (Sigma) every two weeks. Cells were thawed at early passage and cultured for up to 16 weeks in total.

Flow cytometry

To assess cell death, cells were treated as indicated, then collected and stained with Propidium Iodide (PI). For *in vitro* C11BODIPY analysis, cells were treated with test

compounds for the indicated times, then harvested and incubated with C11BODIPY (581/591) for 20 min at 37 degrees. For *ex vivo* C11BODIPY analysis, tumors were filtered and underwent gradient centrifugation, then incubated with 2 μ M C11BODIPY and anti-CD45 antibody. C11BODIPY FITC channel MFI data were normalized to untreated controls. To quantify T-cell cytokine production, mononuclear cells were isolated, stained, and analyzed as previously described (40).

Radiotherapy

Radiotherapy was delivered using a Philips RT250 model orthovoltage unit (Kimtron Medical) or a Small Animal Radiation Research Platform (SARRP, XStrahl Medical and Life Sciences) at a dose rate of approximately 2 Gy per minute as previously described (42). Experiments were performed in the Experimental Irradiation Shared Resource (University of Michigan). Focal irradiation was provided to flank tumors via lead shielding or collimation. Whole abdominal radiotherapy was provided to intraperitoneal tumors with shield above the diaphragm and below the pelvis.

Clonogenic survival assay

Clonogenic survival analysis was conducted as previously described. Normalized surviving fraction represented as relative to compound alone as previously described (42).

Animal studies

Six- to eight-week-old NSG and WT C57BL/6 mice were obtained from the Jackson Laboratory. OT-I colony was maintained internally. All mice were maintained under SPF housing with a maximum of five mice per cage. Mice were randomized to experimental groups when tumors reached 50 mm³ (HT1080, B16F10) or on day of first bioluminescent imaging (ID8). Tumor size was quantified and anti-PD-L1 was provided as previously described (16). For interferon experiments, 65 μ g of human IFN γ was given 24 hours prior to radiation (6-8 Gy, single fraction) as well as two days after radiotherapy. The primary endpoint of all experiments was tumor size. All the animal studies were conducted under the approval of the University of Michigan Committee on Use and Care of Animals (PRO00008278).

Activated T cell supernatant harvest

Single cells suspension was prepared from spleens and lymph nodes from OT-I mice, then stimulated with 5 μ g/ml OVA peptide (Sigma, S7951) in RPMI1640 medium containing 10% FBS. After 3 days, CD8⁺ T cells were isolated via magnetically labeled antibodies (StemCell Technologies, 19853), then cultured in RPMI1640 medium containing IL-2 (R&D Biosystems) and 2-mercaptoethanol (Gibco, 21985023). After 3 days, harvest supernatant and filtered through 0.2 μ m filter prior to subsequent use. For blocking, B16F10 cells were pretreated with 10 μ g/ml anti-IFNGR as well as 10 ng/mL anti-IFN γ antibody.

Immunohistochemistry

Tumor tissues were harvested and fixed in 10% formalin and embedded in paraffin. Staining was performed on tumors treated with the indicated conditions using anti-4-HNE or anti-

SLC7A11 antibody and counterstained using hematoxylin. The alkaline phosphatase optical density was quantified in imageJ. Results were normalized to untreated controls.

RNA sequencing

Cell lines were treated as indicated, and total RNA were purified using an mRNA kit (Qiagen). Libraries were prepared as previously described, and the edgeR package was used to generate reads per kilobase of transcript per million mapped reads (RPKM) values (43). Differential expression analysis was performed using the limma-R package as previously described. Minmax data normalization was used for heatmap generation. Gene set enrichment analysis (GSEA) was performed to identify significantly enriched gene sets (FDR<0.20).

Real time PCR

Total RNA was extracted using trizol and phenol-chloroform phase separation. Reverse transcription was performed using (Invitrogen, K1691). SYBR Green (Invitrogen, 4368702) was used for quantitative PCR with a StepOne Real Time PCR system (Applied Biosystems). β -actin was used as an internal control. Results are represented as fold change from untreated controls. The sequences of primers for qPCR are as follows:

Human SLC7A11 forward: 5'-TGCTGGGCTGATTTTATCTTCG-3',

Human SLC7A11 reverse: 5'-GAAAGGGCAACCATGAAGAGG-3',

Human β -actin forward: 5'-TGGTATCGTGGAAGGACTC-3',

Human β -actin reverse: 5'-AGTAGAGGCAGGGATGATG-3',

mouse ACSL3 forward: 5'-TCCTGGCTGCGATACTTG-3'

mouse ACSL3 reverse: 5'-CCAAAGTCAAGGGCTCGGAT-3',

mouse β -actin forward: 5'-TGAGCTGCGTTTTACACCCT-3',

mouse β -actin reverse: 5'-TTTGGGGGATGTTTGCTCCA-3'

Generation of genetically modified cell lines

Transfected HEK-293T cells with a non-targeted retroviral vector, or a retroviral vector encoding shRNA targeting SLC7A11. Viral containing supernatant was harvested, and HT1080 cells and B16F10 cells with transduced and selected prior to subsequent use

Dharmacon shRNA sequence:

Human shSLC7A11: ATAATAAAGAGATAATACG

Mouse shSLC7A11: ATTAGCTGTATAACTCCAGGG

Crispr-Cas9 constructs (Santacruz Biotechnology) were utilized to generate B16F10 subclones deficient in ACSL4 (sc-424503-NIC), and SLC7A11 (sc-424104-NIC). In

addition, 2-mercaptoethanol (Gibco, 21985023) was added to support SLC7A11 knockout cells growth. lentiCRISPR v2 (addgene, 52961) based constructs were used for knockout of ACSL3 in B16F10 cells, the designed gRNA sequences were GTAATGATATGCCGCAGACG and GGTGTGTACAATGACACCTT. HEK-293T cells were used to produce lentivirus. B16F10 cells were infected with scramble control or gene targeted lentivirus and selected with 2 µg/ml puromycin prior to subsequent use.

To perform the ectopic SLC7A11 rescue assay, a CMV promoter driven mouse SLC7A11-IRES-GFP construct was generated by Gibson Assembly. This construct was transfected into SLC7A11 deficient B16F10 cells. Clones were selected with G418 and fluorescent activated cell sorting.

RNA interference (siRNA)

HT1080 cells were transfected with control or siRNA targeting human ATM (4392420-S532284, Thermo Fisher) or STAT1 (SASI_Rn02_00204016, Sigma) using lipofectamine RNAiMAX (Invitrogen) prior to experimentation.

Radiolabeled cystine uptake assay

HT1080 cells were treated with either IFN γ (10 ng/mL), or radiotherapy (10 Gy), or both for 24 hours. Medium was removed and changed to cystine-free medium. L-¹⁴C-Cystine (0.2 µCi/mL) was added and incubated for 15-45 minutes. Cells were washed and lysed. A Beckman liquid scintillation counter was used to quantify radioactive cystine uptake. Results normalized to total protein as determined by PierceTM BCA Protein Assay Kit(Thermo, 23225).

Glutathione assay

HT1080 cells were treated with either IFN γ (10 ng/mL), or radiotherapy (16 Gy), or both for 24 hours. Glutathione was quantified using the GSH-Glo assay (Promega). Results normalized to cell viability.

Glutamate assay

The Glutamate Colorimetric Assay Kit (BioVision, K629) was used for detection of extracellular glutamate released into the medium. Parental or SLC7A11 knockout B16F10 cells were seeded overnight in the presence of 2-mercaptoethanol to support knockout cell growth. Results normalized to cell viability.

Cell viability assay

Cells were collected and seeded into 96-well plates. To determine the effect of treatment on cell growth and viability, 10% volume of alamar Blue (Bio-Rad) was added directly into the medium and incubated for 4 hours. Absorbance at wavelengths of 570 nm and 600 nm was measured. Results were normalized to untreated controls and shown as relative cell viability (%).

Statistical analysis

Statistical analyses were performed with an unpaired Student's t-test for experiments with two groups (GraphPad Prism). One-way ANOVA was used to compare multiple experimental groups and two-way ANOVA was used to compare continuous outcomes across multiple experimental groups. For all tests, $p < 0.05$ was considered significant. Sample size was not predetermined. Unless noted, samples were independent biological replicates.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by research grants from the NIH/NCI grants for W Zou (CA217648, CA123088, CA099985, CA193136, and CA152470); E Stone and G Georgiou (CA189623); T Lawrence (U01CA216440); A Chinnaiyan (1UM1HG006508); and the NIH through the University of Michigan Rogel Cancer Center Support Grant (P30CA46592). The authors would like to thank all members of the Zou lab for their insightful feedback, as well as acknowledge the support of the University of Michigan Experimental Irradiation Shared Resource, the Research Histology and Immunohistochemistry Core, and the Advanced Genomics Core.

References

1. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations. *Science translational medicine* 2016;8(328):328rv4–rv4 doi 10.1126/scitranslmed.aad7118.
2. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. *Journal for immunotherapy of cancer* 2016;4:51 doi 10.1186/s40425-016-0156-7. [PubMed: 27660705]
3. Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. *Nature* 2017;548:466 doi 10.1038/nature23470 [PubMed: 28759889]
4. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. *Nat Commun* 2017;8:15618 doi 10.1038/ncomms15618. [PubMed: 28598415]
5. Bakhom SF, Kabeche L, Wood MD, Laucius CD, Qu D, Laughney AM, et al. Numerical chromosomal instability mediates susceptibility to radiation treatment. *Nature Communications* 2015;6:5990 doi 10.1038/ncomms6990
6. Morgan MA, Lawrence TS. Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2015;21(13):2898–904 doi 10.1158/1078-0432.CCR-13-3229. [PubMed: 26133775]
7. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3 σ is required to prevent mitotic catastrophe after DNA damage. *Nature* 1999;401:616 doi 10.1038/44188. [PubMed: 10524633]
8. Wang H-H, Wu Z-Q, Qian D, Zaorsky NG, Qiu M-H, Cheng J-J, et al. Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo. *International Journal of Radiation Oncology*Biophysics*Physics* 2018;101(1):49–62 doi: 10.1016/j.ijrobp.2018.01.036.
9. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. *Nature Reviews Cancer* 2004;4:592 doi 10.1038/nrc1412... [PubMed: 15286739]

10. Gebicki JM, Du J, Collins J, Tweeddale H. Peroxidation of proteins and lipids in suspensions of liposomes, in blood serum, and in mouse myeloma cells. *Acta Biochim Pol.* 2000;47:901–11. [PubMed: 11996113]
11. Spitz DR, Azzam EI, Li JJ, Gius D. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology *Cancer Metastasis Rev.* Springer; 2004;23:311–22. [PubMed: 15197331]
12. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* 2012; 149(5): 1060–72 doi 10.1016/j.cell.2012.03.042.. [PubMed: 22632970]
13. Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. *J Exp Med.* jem.rupress.org; 1994;180:525–35. [PubMed: 8046331]
14. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. *Immunity* 2014;41(5):843–52 doi 10.1016/j.immuni.2014.10.019. [PubMed: 25517616]
15. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. *The Journal of Clinical Investigation* 2014; 124(2):687–95 doi 10.1172/jci67313. [PubMed: 24382348]
16. Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. *Nature* 2019;569(7755):270. [PubMed: 31043744]
17. Yang WS, Stockwell BR. Ferroptosis: Death by lipid peroxidation. *Trends in Cell Biology.* 2015;26(3):165–176 doi 10.1016/j.tcb.2015.10.014. [PubMed: 26653790]
18. Cramer SL, Saha A, Liu J, Tadi S, Tiziani S, Yan W, et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. *Nature Medicine* 2016;23:120 doi 10.1038/nm.4232
19. Magtanong L, Ko PJ, To M, Cao JY, Forcina GC, Tarangelo A, et al. Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. *Cell chemical biology* 2019;26(3):420–32.e9 doi 10.1016/j.chembiol.2018.11.016. [PubMed: 30686757]
20. Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. *Nature chemical biology* 2016;13:91 doi 10.1038/nchembio.2239 [PubMed: 27842070]
21. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. *Blood* 2009;114(3):589–95 doi 10.1182/blood-2009-02-206870. [PubMed: 19349616]
22. Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. *Cell* 2016;165(2):272–5. [PubMed: 27058661]
23. Poli G, Schaur RJ, Siems Wa, Leonarduzzi G. 4-Hydroxynonenal: A membrane lipid oxidation product of medicinal interest. *Medicinal research reviews* 2008;28(4):569–631. [PubMed: 18058921]
24. Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. *Nature* 2015;527(7577):249–53 doi 10.1038/nature15520. [PubMed: 26503055]
25. Venkata Narayanan I, Paulsen MT, Bedi K, Berg N, Ljungman EA, Francia S, et al. Transcriptional and post-transcriptional regulation of the ionizing radiation response by ATM and p53. *Sci Rep* 2017;7:43598 doi 10.1038/srep43598. [PubMed: 28256581]
26. Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. *Elife* 2014;3:e02523. [PubMed: 24844246]
27. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of Ferroptotic Cancer Cell Death by GPX4. *Cell* 2014; 156(0):317–31 doi 10.1016/j.cell.2013.12.010. [PubMed: 24439385]

28. Purbey PK, Scumpia PO, Kim PJ, Tong A-J, Iwamoto KS, McBride WH, et al. Defined Sensing Mechanisms and Signaling Pathways Contribute to the Global Inflammatory Gene Expression Output Elicited by Ionizing Radiation. *Immunity* 2017;47(3):421–34.e3 doi 10.1016/j.immuni.2017.08.017. [PubMed: 28930658]
29. Chen P-H, Wu J, Ding C-KC, Lin C-C, Pan S, Bossa N, et al. Kinome screen of ferroptosis reveals a novel role of ATM in regulating iron metabolism. *Cell Death & Differentiation* 2019 doi 10.1038/S41418-019-0393-7.
30. Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson C, Chessa L, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. *Science* 1998;281(5383):1674–7. [PubMed: 9733514]
31. Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. *Cell* 2016; 165(5):1092–105. [PubMed: 27133165]
32. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2009; 15(17):5379–88 doi 10.1158/1078-0432.Ccr-09-0265. [PubMed: 19706802]
33. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature* 2015;520(7547):373–7 doi 10.1038/nature14292. [PubMed: 25754329]
34. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. *Cell* 2017;171(2):273–85 doi 10.1016/j.cell.2017.09.021. [PubMed: 28985560]
35. Kruiswijk F, Labuschagne C, Vusden K, p53 in survival, death and metabolic health: a lifeguard with a licence to kill. *Nature Reviews Molecular Cell Biology* 2015; 16(7):393–405. doi: 10.1038/nrm4007 [PubMed: 26122615]
36. Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. *Science advances* 2018;4(6):eaat1719. [PubMed: 29938225]
37. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12(4):252–64 doi 10.1038/nrc3239. [PubMed: 22437870]
38. Ribas A Adaptive Immune Resistance: How Cancer Protects from Immune Attack. *Cancer discovery* 2015;5(9):915–9 doi 10.1158/2159-8290.cd-15-0563. [PubMed: 26272491]
39. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. *Nature Medicine* 2003;9(5):562–7 doi 10.1038/nm863.
40. Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. *The Journal of Clinical Investigation* 2018;128(2):805–15 doi 10.1172/JCI96113. [PubMed: 29337305]
41. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nature Medicine* 2004;10(9):942–9 doi 10.1038/nm1093.
42. Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, et al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2014;20):5085–96 doi 10.1158/1078-0432.ccr-14-1038. [PubMed: 25117293]
43. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics (Oxford, England)* 2010;26(1):139–40 doi 10.1093/bioinformatics/btp616.

Significance:

This paper describes ferroptosis as a previously unappreciated mechanism of action for radiotherapy. Further, it shows that ferroptosis is a novel point of synergy between immunotherapy and radiotherapy. Finally, it nominates SLC7A11, a critical regulator of ferroptosis, as a mechanistic determinant of synergy between radiotherapy and immunotherapy.




Figure 1. Radiotherapy induces tumor cell ferroptosis

A, ID8 tumor growth following radiotherapy (8 Gy, single fraction, arrow) and/or liproxstatin-1 treatment (50 mg/kg, administered daily for 5 days, bar) *in vivo*. n=10 per group, ns P>0.05, ****P<0.0001, two-way ANOVA.

B, B16F10 tumor lipid ROS following radiotherapy (8 Gy, single fraction) and/or liproxstatin-1 treatment (50 mg/kg, administered daily for 5 days) *in vivo*. DMSO, n=17; RT, n=14; Liproxstatin-1, n=10; RT+liproxstatin-1, n=12. ns P>0.05, ****P<0.001, two-way ANOVA.

C, D, RSL-3 resistant B16F10 (**C**) tumor growth *in vivo* and (**D**) tumor lipid ROS following radiotherapy (8 Gy, single fraction, arrow). n=14 per group, (**C**), ****p<0.0001, two-way ANOVA; (**D**) ns P>0.05, **P<0.01, two-way ANOVA.

E, Erastin resistant ID8 tumor growth following radiotherapy (8 Gy, single fraction, arrow) *in vivo*. n=10 per group. ns P>0.05, *P<0.05, two-way ANOVA.

F, Clonogenic survival of HT1080 cells treated with DMSO, ferrostatin-1 (5 μM), liproxstatin-1 (5 μM), trolox (200 μM), DFO (2 μM) as indicated then irradiated (6 Gy) *in vitro*. Representative biological triplicate shown, mean±SD. ****p<0.0001, one-way ANOVA.

G, HT1080 lipid ROS *in vitro* following radiotherapy (8 Gy) *in vitro*. Representative biological triplicates shown, mean±SD. ****P<0.0001, unpaired Student's t-test.

H, Clonogenic survival of HT1080 cells following treatment with DMSO, RSL-3 (0.05 μM), erastin (2 μM), atorvastatin (5 μM), or sulfasalazine (5 μM) as indicated and radiotherapy (4 Gy) *in vitro*. Representative biological triplicate shown, mean±SD. *P<0.05, **P<0.01, ***P<0.001, one-way ANOVA.

I, Clonogenic survival of HT1080 at indicated radiotherapy dose following cyst(e)inase (10 μM) treatment *in vitro*. Representative biological triplicates shown, mean±SD. **P<0.005, unpaired Student's t-test.

J, B16F10 cell death following sulfasalazine (SAS, 5 μM) or cyst(e)inase (10 μM) and irradiation (20 Gy) *in vitro*. ****P<0.0001, two-way ANOVA.

K, L, B16F10 tumor growth (**K**) and tumor lipid ROS (**L**) following radiotherapy (8 Gy, one fraction, arrow) and/or cyst(e)inase (87.5 mg/kg, arrowhead) *in vivo*. n=10 per group. ns P>0.05, ****P<0.0001, two-way ANOVA.

M, ACSL4 knockout and parental B16F10 tumor growth following radiotherapy (10 Gy, single fraction, arrow) *in vivo*. n=10 per group. ****P<0.0001, two-way ANOVA.

N, ACSL3 knockout and parental B16F10 tumor growth following radiotherapy (8 Gy, single fraction, arrow) *in vivo*. n=10 per group. ***P<0.001, two-way ANOVA.

O, Relative lipid ROS in B16F10 cells treated with SAS (5 μM), RSL-3 (0.05 μM) or cyst(e)inase (10 μM) and radiotherapy (2 Gy) *in vitro*. Representative biological triplicate shown, mean±SD. ***P<0.001, two-way ANOVA.

P, Tumor lipid ROS in B16F10 tumors following indicated radiotherapy dose fractionation *in vivo*. n=8-10 per group. **P<0.005, ***P<0.001, ****P<0.0001, one-way ANOVA. Data are representative of at least two independent experiments (A-P).




Figure 2: CD8⁺ T cells promote radiotherapy induced ferroptosis via IFN γ

A, B16F10 tumor growth following irradiation (8 Gy, single fraction, arrow) and/or CD8⁺ T cells depletion (arrowhead) *in vivo*. n=20 per group, ****p<0.0001, two-way ANOVA.

B, Clonogenic survival of B16F10 cells treated with naive or activated (OT-I) CD8⁺ T cell supernatant following RT (4 Gy) *in vitro*. Representative biological triplicate shown, mean \pm SD. *P<0.05, one-way ANOVA.

C, Relative lipid ROS of B16F10 cells treated with naive or activated (OT-I) CD8⁺ T cell supernatant following RT (4 Gy) with or without IFN γ signaling blockade *in vitro*. Representative biological triplicate shown, mean \pm SD. ***P<0.001, ****P<0.0001, two-way ANOVA.

D, Clonogenic survival of ID8 cells treated with IFN γ (10 ng/ml) and/or RT (4 Gy) *in vitro*. Representative biological triplicate shown, mean \pm SD. ****p<0.0001, two-way ANOVA.

E, ID8 cell relative lipid ROS following treatment of and/or RT (4 Gy) *in vitro*. ****p<0.0001, two-way ANOVA.

F, Cell death in B16F10 following treatment with IFN γ (10 ng/ml) and/or RT (20 Gy) *in vitro*. Representative biological triplicate shown, mean \pm SD. ****p<0.0001, two-way ANOVA.

G, Clonogenic survival of HT1080 following treatment with IFN γ (10 ng/ml), liproxstatin-1 (5 μ M), and/or RT (4 Gy) *in vitro*. Representative biological triplicate shown, mean \pm SD. ****P<0.0001, two-way ANOVA.

H, I, HT1080 tumor growth (**H**) and 4-HNE quantification (**I**) following treatment with RT (8 Gy, one fraction, arrow) and/or IFN γ (65 μ g/mouse, intraperitoneal, arrowhead) *in vivo*. n=10 per group. ***P<0.001, ****P<0.0001, two-way ANOVA.

J, HT1080 tumor growth following treatment with liproxstatin-1 (intraperitoneal, 50 mg/kg, bar) and/or IFN γ (65 μ g/mouse, arrowhead) and radiotherapy (6 Gy, arrow) *in vivo*. DMSO,

n=10; Liproxstatin-1, n=11; IFN γ +RT, n=15; IFN γ +RT+lipoxstatin-1, n=14, ***P<0.001, ****P<0.0001, two-way ANOVA.

Data are representative of at least two independent experiments (A-J).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3: Radiotherapy and IFN γ synergistically suppress system SLC7A11

A, Normalized heatmap of HT1080 RNA-seq following treatment with IFN γ (10 ng/ml), and/or RT (20 Gy) *in vitro*.

B, qPCR for SLC7A11 in HT1080 cells treated with IFN γ (10 ng/ml) and/or RT (10 Gy) *in vitro*. **P<0.01, ***P<0.001, ****P<0.0001, two-way ANOVA.

C, Immunoblot for SLC7A11 in HT1080 cells treated with IFN γ (10 ng/ml) and/or RT (10 Gy) *in vitro*.

D, Representative SLC7A11 immunohistochemistry in HT1080 tumors treated as in Fig. 2H *in vivo*.

E, 14 C-cystine uptake in HT1080 cells treated with IFN γ (10 ng/ml) and/or RT (10 Gy) *in vitro*. **P<0.01, ***P<0.001, ****P<0.0001, two-way ANOVA.

F, Glutathione quantification in HT1080 cells treated with IFN γ (10 ng/ml) and/or RT (16 Gy) *in vitro*. ****P<0.0001, two-way ANOVA.

G, Immunoblot in HT1080 cells irradiated with RT (10 Gy) and/or KU60019 *in vitro*.

H, HT1080 lipid ROS following RT (4 Gy) and/or KU60019 (1 μ M) *in vitro*. Representative biological triplicate shown, mean \pm SD. ns P>0.05, *P<0.05, two-way ANOVA.

I, Immunoblot for indicated in HT1080 cells treated with 10 Gy (RT) and/or siRNA targeting ATM (si-ATM) *in vitro*.

J, Immunohistochemical quantification of SLC7A11 in HT1080 tumors of the indicated genotypes following treatment with RT (8 Gy, single fraction, arrow) *in vivo*. ns P>0.05, ****P<0.0001, two-way ANOVA.

K, Immunoblot for indicated protein in HT1080 cells treated with IFN γ (10 ng/ml) and/or siRNA targeting STAT1 (si-STAT1) *in vitro*.

L, Immunohistochemical quantification of SLC7A11 in HT1080 tumors, treated with or without IFN γ (65 μ g/mouse, intraperitoneal). ns P>0.05, ****P<0.0001, two-way ANOVA.

M, Clonogenic survival of HT1080 cells at indicated RT dose following shRNA targeting SLC7A11 (shSLC7A11) and liproxstatin-1 treatment *in vitro*. Representative biological triplicate shown, mean \pm SD. ***P<0.001, one-way ANOVA.

N, O, SLC7A11 knockout B16F10 cells tumor growth (**N**) and tumor lipid ROS level (**O**) following irradiation (8 Gy, single fraction, arrow) *in vivo*. Parental, n=15; Parental+RT, n=19; SLC7A11 KO, n=17; SLC7A11 KO+RT, n=18. (**N**) ***P<0.001, two-way ANOVA; (**O**) **P<0.01, ****P<0.0001, two-way ANOVA.

P, Clonogenic survival of wild type and SLC7A11 overexpressing HT1080 cells following 8 Gy and IFN γ (10 ng/ml) *in vitro*. **P<0.001, unpaired Student's t-test.

Q, SLC7A11 knockout with/without SLC7A11 overexpression B16F10 cells tumor growth following irradiation (8 Gy, single fraction, arrow) *in vivo*. n=10; *P<0.05, ****P<0.0001, two-way ANOVA

Data are representative of at least two independent experiments (A-Q).




Figure 4: Radiotherapy and immunotherapy synergistically induce tumoral ferroptosis
A, B, B16F10 (A) tumor growth and (B) tumor lipid ROS following treatment with RT (8 Gy) and/or anti-CTLA-4 mAb *in vivo*. Isotype Control (IgG), n=16; RT, n=20; anti-CTLA-4 mAb (aCTLA-4), n=18; RT+a-CTLA-4 mAb (aCTLA-4+RT), n=20. (A) *P<0.05, ***P<0.001, ****P<0.0001, two-way ANOVA; (B) *P<0.05, ***P<0.001, two-way ANOVA.
C, Intratumoral CD8⁺ T cell proliferation *in vivo*. *P<0.05, **P<0.01, two-way ANOVA.
D, IFN_γ production by intratumoral CD8⁺ T cells *in vivo*. *P<0.05, two-way ANOVA.
E, Granzyme B production by intratumoral CD8⁺ T cells *in vivo*. *P<0.05, ***P<0.001, two-way ANOVA.

F, B16F10 tumor growth following treatment with liproxstatin-1 (50 mg/kg, intraperitoneal, bar) and/or RT (8 Gy, single dose, arrow) with anti-CTLA-4 mAb (arrowhead) *in vivo*. Isotype Control (IgG), n=16; RT, n=20; Liproxstatin-1, n=8; RT plus anti-CTLA-4 mAb and liproxstatin-1 (aCTLA-4+RT+liproxstatin-1), n=20. ****P<0.0001, two-way ANOVA.

G, H, ID8 (**G**) tumor growth and (**H**) lipid ROS following treatment with RT (8 Gy, single dose, arrow) and/or anti-CTLA-4 mAb (arrowhead) *in vivo*. n=8 per group. *P<0.01, ***P<0.001, two-way ANOVA.

I, J, B16F10 tumor cell growth (**I**) and tumor lipid ROS (**J**) following treatment with RT (8 Gy, single dose, arrow) and/or anti-PD-L1 mAb (200 µg/mouse, arrowhead) *in vivo*. Isotype Control (IgG), n=15; RT, n=16, anti-PD-L1 mAb (aPD-L1); n=17, RT and anti-PD-L1 mAb (aPD-L1+RT), n=17. (**I**) ****P<0.0001, two-way ANOVA; (**J**) *P<0.05, **P<0.01, two-way ANOVA.

K, L, RSL-3 resistant B16F10 tumor growth *in vivo* (**K**) and tumoral lipid ROS (**L**) were treated with RT (8 Gy, one fraction, arrow) and anti-PD-L1 mAb (200 µg/mouse, arrowhead). Parental IgG, n=14; Parental RT+aPD-L1, n=16; RSL-resis IgG, n=14; RSL-resis RT+aPD-L1, n=16. (**K**) ns P>0.05, ****P< 0001, two-way ANOVA; (**L**) ns P>0.05, ****P<0.0001, two-way ANOVA.

M, RSL-3 resistant or parental ovalbumin expressing B16F10 tumor growth following adoptive transfer of activated OT-I T cells *in vivo* (arrowhead). n=10. ****p<0.0001, two-way ANOVA.

N, O, SLC7A11 knockout B16F10 cells tumor growth (**N**) and rechallenge inoculation (**O**) following irradiation (8 Gy, single fraction, arrow) and anti-PD-L1 treatment (200 µg/mouse, arrowhead) *in vivo*. Parental, n=10; Parental+aPD-L1+RT, n=10; SLC7A11 KO, n=10; SLC7A11 KO+aPD-L1+RT, n=25; Naïve, n=10. ****p< 0.0001, two-way ANOVA.

Data are representative of at least two independent experiments (A-O).